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Abstract
Background: The studies on cancer-stem-cells (CSCs) have attracted so much attention in recent
years as possible therapeutic implications. This study was carried out to investigate the gene
expression profile of CSCs in human lung adenocarcinoma A549 cells.
Results: We isolated CSCs from A549 cell line of which side population (SP) phenotype revealed
several stem cell properties. After staining the cell line with Hoechst 33342 dye, the SP and non-
side population (non-SP) cells were sorted using flow cytometric analysis. The mRNA expression
profiles were measured using an Affymetrix GeneChip® oligonucleotide array. Among the sixty one
differentially expressed genes, the twelve genes inclusive three poor prognostic genes; Aldo-keto
reductase family 1, member C1/C2 (AKR1C1/C2), Transmembrane 4 L six family member 1
nuclear receptor (TM4SF1), and Nuclear receptor subfamily 0, group B, member 1 (NR0B1) were
significantly up-regulated in SP compared to non-SP cells.
Conclusion: This is the first report indicating the differences of gene expression pattern between
SP and non-SP cells in A549 cells. We suggest that the up-regulations of the genes AKR1C1/C2,
TM4SF1 and NR0B1 in SP of human adenocarcinoma A549 cells could be a target of poor prognosis
in anti-cancer therapy.
Background
Cancer stem cell hypothesis is the tumoral cells which
have stem cell features such as self-renewal, high migra-
tion capacity, drug resistance, and aberrant differentiation
which constitute the heterogeneous population of tumor
[1,2]. Tissue-specific stem cells are defined by their ability
to self-renew and to produce the well differentiated and
functional cells within an organ. Differentiated cells are
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generally short-lived; in skin and blood for example, they
are produced from a small pool of long-lived stem cells
that last throughout the life [3-6]. Therefore, stem cells are
necessary for tissue development, replacement, and repair
[7]. On the other hands, the longevity of stem cells make
them susceptible to accumulating genetic damage and
thereby representing the growth root for cancer recurrence
following treatment [8]. It was reported that some of the
tumor stem cells can survive chemotherapy and support
re-growth of the tumor mass [9].
Cancer stem cells (CSCs) were first identified in 1990s in
hematological malignancies, mainly acute myelogenous
leukemia (AML) and also in other subtypes like AML M0,
M1, M2, M4, and M5, chronic myeloid leukemia (CML),
acute lymphoblastic leukemia (ALL), and multiple mye-
loma [10,11]. CSCs are also known in solid tumors like
breast, brain, lung, prostrate, testis, ovary, stomach, colon,
skin, liver, and pancreas [12-17]. A character of stem cells,
termed "side population (SP)", has been identified using
Hoechst 33342 dye. The flow cytometric analysis makes
sorting possible either to SP or non-SP cells. The SP cells
have been isolated from various types of adult tissue
where they demonstrate stem cell activity [18-23]. The
findings of these previous studies suggest that the SP phe-
notype represents a common feature of stem cells.
We performed our work on human lung adenocarcinoma
A549 cells (of which SP phenotype revealed several stem
cell properties [24]) to identify the genes, which make the
CSCs of poor prognostic phenotype and evaluate the gene
expression intensities of SP and non-SP cells using oligo-
nucleotide micro-array. The reasons why the A549 cell
line was selected, because it has a relatively high propor-
tion of SP cells compared to other cell lines [25] and is
more chemo-resistant particularly to platinum drugs [26].
Results
The distinct gene regulations in SP cells
We sorted A549 cell line to SP and non-SP cells (Fig. 1)
and compared the gene expression intensities of both
cells. Official symbols and gene names were used in
accordance with the symbol and name lists approved by
HUGO (Human genome organization) Gene Nomencla-
ture Committee (Table 1) [27]. Following data analysis,
12 genes were considered as up-regulated in SP cells
(TM4SF1 has 2 probe ID) (fold changes are shown in
Table 2), whereas, 49 genes were down-regulated (Fig. 2).
Since we focused on distinct gene regulations, the stu-
dent's t'-test was not employed to prevent loss of up-regu-
lated genes in all of three chip data, though it had large
chip variations.
Validation of gene regulations
To confirm the fold changes of AKR1C1  in chip data,
quantitative real time – reverse transcriptase PCR was
employed. The relative fold changes in SP compared to
non-SP cells were 3.11 ± 0.92 and 2.88 ± 0.17 in micro-
array and qrt- rtPCR, respectively (Fig. 3).
Discussion
Based on the cancer stem cell hypothesis, we assumed that
the up-regulation of certain genes that are related to poor
prognosis (high migration capacity or drug resistance) in
SP of cancer cells could be a target for therapeutic index.
In the present study, we found some genes that are related
to drug resistance, such as AKR1C1/C2 and NR0B1, or
cancer metastasis, such as TM4SF1, were up-regulated in
SP cells of human lung adenocarcinoma A549 cell line.
Furthermore, the up-regulated gene, ABCG2, has been
noticed to be as an indicator for sorting SP cells by
Hoechst 33342 staining [24]. It was reported that ABCG2
pumping out the drugs was associated with multi-drug
resistance in many cancers [28,29] and/or effects higher
levels of DNA repair and hence lowered the ability to
apoptosis [30].
AKR1C belongs to a superfamily of monomeric, cytosolic
NADP(H)-dependent oxidoreductases that catalyzes the
metabolic reduction and either activate or inactivate sev-
eral xenobiotics [31,32]. In humans, at least four isoforms
of AKR1C (AKR1C1~4) have been identified [33].
AKR1C1/AKR1C3 was known to inactivate progesterone,
which could alter the progesterone/estrogen ratio in cer-
tain cancers [34,35]. Additionally, AKR1C1/C2 inhibitors
were reported as potential anti-neoplastic agents [36,37].
Sorting of SP and non-SP cells by FACSVantage SE Figure 1
Sorting of SP and non-SP cells by FACSVantage SE.Molecular Cancer 2007, 6:75 http://www.molecular-cancer.com/content/6/1/75
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Table 1: The approved gene symbols and names in reference to HUGO Gene Nomenclature
Gene symbol Gene name
AKR1C1; AKR1C2 aldo-keto reductase family 1, member C1 (dihydrodiol dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase); aldo-keto reductase family 1, member C2 (dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, type III)
TM4SF1 transmembrane 4 L six family member 1
NR0B1 nuclear receptor subfamily 0, group B, member 1
LRPPRC leucine-rich PPR-motif containing
SFRS3 splicing factor, arginine/serine-rich 3
ABCG2 ATP-binding cassette, sub-family G (WHITE), member 2
Unidentified 1 adult retina protein
KRT4 keratin 4
ZNF567 zinc finger protein 567
IL6R interleukin 6 receptor
PAMCI peptidylglycine alpha-amidating monooxygenase COOH-terminal interactor
ZNF267 zinc finger protein 267
NEFL neurofilament, light polypeptide 68 kDa
SFMBT2 Scm-like with four mbt domains 2
FSTL1 follistatin-like 1
TMEPAI transmembrane, prostate androgen induced RNA
COL5A1 collagen, type V, alpha 1
SLC6A15 solute carrier family 6, member 15
COL1A1 collagen, type I, alpha 1
NTRK3 neurotrophic tyrosine kinase, receptor, type 3
CDH2 cadherin 2, type 1, N-cadherin (neuronal)
ANXA8 annexin A8
THBD thrombomodulin
RAB3B RAB3B, member RAS oncogene family
ADAM19 ADAM metallopeptidase domain 19 (meltrin beta)
COL4A2 collagen, type IV, alpha 2
IGFBP7 insulin-like growth factor binding protein 7
COL4A1 collagen, type IV, alpha 1
IFI16 interferon, gamma-inducible protein 16
GLIPR1 GLI pathogenesis-related 1 (glioma)
TGM2 transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)
COL4A1 collagen, type IV, alpha 1
IGFBP7 insulin-like growth factor binding protein 7
MYL9 myosin, light chain 9, regulatory
Unidentified 2 CDNA FLJ44429 fis, clone UTERU2015653
MATN2 matrilin 2
TNFAIP6 tumor necrosis factor, alpha-induced protein 6
FRMD5 FERM domain containing 5
RUNX2 runt-related transcription factor 2
TMEPAI transmembrane, prostate androgen induced RNA
GLIPR1 GLI pathogenesis-related 1 (glioma)
NPTX1 neuronal pentraxin I
GLIPR1 GLI pathogenesis-related 1 (glioma)
SPARC secreted protein, acidic, cysteine-rich (osteonectin)
COL5A1 collagen, type V, alpha 1
COL1A1 collagen, type I, alpha 1
B4GALT1 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1
Unidentified 3 -
TNS1 tensin 1
SPOCK1 sparc/osteonectin, cwcv and kazal-like domains proteoglycan (testican) 1
MOBKL2B MOB1, Mps One Binder kinase activator-like 2B (yeast)
ID2 inhibitor of DNA binding 2, dominant negative helix-loop-helix protein
C4orf18 chromosome 4 open reading frame 18
COL5A1 collagen, type V, alpha 1
TAGLN transgelin
CXCR7 chemokine (C-X-C motif) receptor 7
Unidentified 4 Transcribed locus, moderately similar to XP_517655.1 PREDICTED: similar to KIAA0825 protein [Pan troglodytes]
COL5A1 collagen, type V, alpha 1
MOBKL2B MOB1, Mps One Binder kinase activator-like 2B (yeast)
TAGLN transgelin
SPARC secreted protein, acidic, cysteine-rich (osteonectin)Molecular Cancer 2007, 6:75 http://www.molecular-cancer.com/content/6/1/75
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The high expression of AKR1C was considered as a poor
prognostic factor in patients with non-small-cell lung can-
cer [38], and it was enriched in hepatocellular carcinoma
than normal hepatic cells [39]. A previous study evaluated
the relationship between the AKR1C and drug resistance
and revealed that the over expression of AKR1C1/C2 led
to drug resistance in non-small-cell lung cancer cells [26].
A public database (Gene Expression Omnibus (GEO),
NCBI) [40] has shown significant up-regulation of
AKR1C1 in smokers (Figure 4A). Similar trends were also
reported in lung cancer patients [41,42]. This means that
smoking can alter the regulation of certain genes related to
poor prognosis such as AKR1C1. Moreover, AKR1C1 was
suggested as a marker of stem-like cells in thyroid cancer
cell lines, though it was not proved by the authors [41].
From the data of GEO, the TM4SF1 gene, which is
believed to be involved in cancer invasion and metastasis
[44] was also up-regulated in smokers (Figure 4B), and
metastatic form of colon cancer patients compared to pri-
mary form of colon cancer patients (Figure 4C). TM4SF1
was also suggested as a possible marker of stem-like cells
in thyroid cancer cells [41]. However, we could not find
out the GEO data that match to tumor genesis of the up-
regulated NR0B1, though up-regulated NR0B1 gene was
required for the transformed phenotype of certain sar-
coma [45].
Conclusion
It is still unclear how the cancer stem cells express poor
prognostic phenotype in cancer, but we found for the first
time that several genes related to chemo-resistance and
metastasis are up-regulated in SP cells compared to non-
SP cells. Therefore, enrichment of AKR1C1/C2, TM4SF1
and NR0B1 in SP of A549 cells might be a target of poor
prognosis in cancer therapy.
Methods
Cell culture
A549 cells, a representative human lung adenocarcinoma
cell line, were obtained from American Type Culture Col-
lection (ATCC, VA, USA). The cells were cultured on F-12K
nutrient mixture, Kaighn's modification (1×) liquid
(Gibco, CA, USA) supplemented with 10% fetal bovine
serum (FBS) (Genetron Life Technology, INC., CA, USA)
and 1% of penicillin/streptomycin (P/S) (Gibco, CA,
USA) on standard plastic tissue culture dishes (SPL Life
Sciences, Seoul, Republic of Korea) and incubated in an
atmosphere of 95% air/5% CO2 at 37°C.
Fluorescence activated cell sorting (FACS) for SP and non-
SP cells
The cells were detached with trypsin (Gibco, CA, USA),
washed with phosphate buffer solution (PBS)/2% FBS,
and resuspended at 1 × 106 cells per ml in pre-warmed
Hanks' balanced salt solution (HBSS; Gibco, CA, USA)/
10% FBS. Hoechst 33342 dye (Sigma, St. Louis, MO, USA)
was then added to this portion (final concentration: 5 μg/
ml), and incubation continued for 90 min at 37°C. After
washing with PBS/2% FBS, the cells re-suspended in ice-
cold HBSS/10% FBS were labeled with 2 μg/ml propid-
ium iodide (Sigma, St. Louis, MO, USA) to distinguish
live from dead cells prior to analysis. SP analysis and sort-
ing were done using a FACSVantage SE (BD Biosciences,
CA, USA). The Hoechst 33342 dye excited at 350 nm
using UV laser and the DM610 SP was used to distinguish
the red from the blue fluorescence signals. The EF675-LP
(Hoechst Red) and BP450/20 nm (Hoechst Blue) filters
were then installed in front of the PMT detector.
RNA isolation and oligonucleotide microarray analysis
We prepared total RNA from approximately 2 × 106 SP or
non-SP cells with Qiagen RNeasy Mini kit (Qiagen, CA,
Table 2: Gene list up-regulated in SP cells compared to non-SP cells
Probe ID Genbank Gene symbol Fold change (Mean ± SD)
217626_at BF508244 AKR1C1; AKR1C2 3.11 ± 0.92
238168_at AI760128 TM4SF1 2.77 ± 0.66
206645_s_at NM_000475 NR0B1 2.78 ± 0.81
1557360_at CA430402 LRPPRC 2.72 ± 0.37
215033_at AI189753 TM4SF1 2.72 ± 0.46
232392_at BE927772 SFRS3 2.51 ± 0.08
209735_at AF098951 ABCG2 2.51 ± 0.37
238476_at AA481560 Unidentified 1* 2.43 ± 0.18
213240_s_at X07695 KRT4 2.43 ± 0.28
235648_at AA742659 ZNF567 2.47 ± 0.75
205945_at NM_000565 IL6R .36 ± 0.24
210335_at AF056209 PAMCI 2.31 ± 0.29
219540_at AU150728 ZNF267 2.20 ± 0.27Molecular Cancer 2007, 6:75 http://www.molecular-cancer.com/content/6/1/75
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Gene clustering of up-regulated genes in SP and non-SP cells Figure 2
Gene clustering of up-regulated genes in SP and non-SP cells. After normalizing each chip to the 50th percentile of the 
measurements taken that chip, gene-probes scored less than 0.1 either in SP or non-SP were excluded from data analysis. Only 
matched up-regulated genes in SP compared to non- SP cells are selected in each step of chip data analysis. The 12 genes and 
46 genes were considered as up-regulated in SP and non-SP cells, respectively.Molecular Cancer 2007, 6:75 http://www.molecular-cancer.com/content/6/1/75
Page 6 of 8
(page number not for citation purposes)
USA) according to the instruction of the manufacturer.
The RNAs were subjected to GeneChip® expression array
in full commercial service with two-cycle target labeling
(SeouLin Bioscience, Seoul, Republic of Korea). Briefly,
cDNA were synthesized from total RNA using T7-Oligo
(dT) primers. Using that cDNA, biotinylated cRNA was
then synthesized. Fifteen μg of the labeled cRNA was
hybridized to a Human Genome U133 Plus 2.0 Array
(Affymetrix, CA, USA). Array image was scanned and ana-
lyzed using Genechip operating software (GCOS)
(Affymetrix, CA, USA).
Quantitative real-time rt-PCR (qrt-rtPCR)
To validate the fold changes in the expression intensity of
SP and non-SP cells in microarray data, we performed qrt-
rtPCR using SYBR Premix Ex Taq Perfect Real Time kit
(TaKaRa Bio, Ohtsu, Japan) in a SmartCycler (Cepheid,
CA, USA) according to the manufacturer's instruction. The
cycle threshold value, which was determined using second
derivative, was used to calculate the normalized expres-
sion of the indicated genes using Smartcycler Software
(Cepheid, CA, USA). The following primer pairs were
used:  GAPDH  (as an internal control); F-primer
5'CGACCACTTTGTCAAGCTCA3' and R-primer
5'AGGGGAGATTCAGTGTGGTG3',  AKR1C1;AKR1C2; F-
primer 5'GTGGAAGCTGACCAGGTTGT3' and R-primer
5'AAGCCGTGTTCTTTCTGCTG3'.
Microarray data analysis
We used GeneSpring GX 7.3.1 software (Agilent Technol-
ogies, CA, USA) to normalize and analyze the microarray
data. Following normalization of each chip to the 50th
percentile of the measurements taken that chip, probes
(genes) scored less than 0.1 both in SP and non-SP cells
were excluded from the data analysis. Only matched up-
regulated genes in SP and non-SP cells were selected from
each step of chip (gene expression microarray) data anal-
ysis. More than 2 fold changes in all chip data were con-
sidered as up-regulated. Standard curve method was used
to analyze qrt-rtPCR for confirmation of fold changes in
chip data.
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